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The gene for cystathionine b-synthase (CBS) is located on chromosome 21 and is overexpressed in children with
Down syndrome (DS), or trisomy 21. The dual purpose of the present study was to evaluate the impact of
overexpression of the CBS gene on homocysteine metabolism in children with DS and to determine whether the
supplementation of trisomy 21 lymphoblasts in vitro with selected nutrients would shift the genetically induced
metabolic imbalance. Plasma samples were obtained from 42 children with karyotypically confirmed full trisomy
21 and from 36 normal siblings (mean age 7.4 years). Metabolites involved in homocysteine metabolism were
measured and compared to those of normal siblings used as controls. Lymphocyte DNA methylation status was
determined as a functional endpoint. The results indicated that plasma levels of homocysteine, methionine, S-
adenosylhomocysteine, and S-adenosylmethionine were all significantly decreased in children with DS and that their
lymphocyte DNAwas hypermethylated relative to that in normal siblings. Plasma levels of cystathionine and cysteine
were significantly increased, consistent with an increase in CBS activity. Plasma glutathione levels were significantly
reduced in the children with DS and may reflect an increase in oxidative stress due to the overexpression of the
superoxide dismutase gene, also located on chromosome 21. The addition of methionine, folinic acid, methyl-B12,
thymidine, or dimethylglycine to the cultured trisomy 21 lymphoblastoid cells improved the metabolic profile in
vitro. The increased activity of CBS in children with DS significantly alters homocysteine metabolism such that the
folate-dependent resynthesis of methionine is compromised. The decreased availability of homocysteine promotes
the well-established “folate trap,” creating a functional folate deficiency that may contribute to the metabolic
pathology of this complex genetic disorder.
Introduction
Down syndrome (DS [MIM 190685]), or trisomy 21, is
a complex metabolic and genetic disorder that stems
from the failure of chromosome 21 to segregate normally
during meiosis (Epstein 1995). It is the first clinically
defined syndrome shown to be chromosomal in origin
and has been the prototype for clinical, cytogenetic, and
molecular investigation into mechanisms and manage-
ment of human aneuploid conditions. The origin of the
extra chromosome 21 has been shown to be maternal
in ∼93% of cases, with ∼7% of cases due to paternal
nondisjunction and a very small proportion of cases due
to postzygotic mitotic nondisjunction (mosaics) (Has-
sold and Sherman 2000). DS is the most common genetic
cause of human mental retardation and occurs with a
prevalence of ∼1/700–800 live births (Krivchenia et al.
1993). In addition to mental deficiency, 40%–50% of
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children with DS have congenital heart defects (primarily
endocardial cushion defects), ∼5% have gastrointestinal
anomalies, and there is a 15–20-fold–increased risk of
transient myelodysplasia and childhood leukemia (Ko-
renberg et al. 1994; Torfs and Christianson 1998). In
addition, immunologic disorders, such as celiac disease,
thyroid dysfunction, and diabetes, are prevalent in chil-
dren with DS (Jannson and Johansson 1995). The ex-
cessive synthesis of multiple gene products derived from
overexpression of the genes present on chromosome 21
is thought to underlie both the dysmorphic features and
the pathogenesis of the neurological, immunologic, en-
docrine, and biochemical abnormalities that are char-
acteristic of DS. The successful management of the clin-
ical problems and unique pharmacological sensitivities
of these children is a major medical challenge and de-
pends on an understanding of the unique metabolic im-
balance induced by overexpression of the constitutively
expressed genes on chromosome 21.
The sequence and gene catalog for chromosome 21
have recently been published, with 97.7% coverage of
21q (Hattori et al. 2000). This analysis has revealed
127 known genes, 98 predicted genes, and 59 pseudo-
genes. Although there has been early speculation that
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Figure 1 Overview of interactive and interdependent reactions involved in cellular one-carbon metabolism, with emphasis on the two
major metabolic functions of these pathways: normal DNA synthesis/repair and normal cellular methylation reactions. These twomajor functions
intersect at the folate/B12–dependent methionine synthase reaction, which regenerates methionine from homocysteine and, at the same time,
generates metabolically active THF for DNA/RNA nucleotide synthesis. Two genes (CBS and SOD) on chromosome 21 that are overexpressed
in individuals with DS are shown in circles. Arrows indicate direct and indirect alterations in metabolites, induced by CBS overexpression in
individuals with DS.
the phenotypic abnormalities in individuals with DS
were caused by a 50% overexpression of all genes on
chromosome 21, recent evidence suggests that this view
is too simplistic and that certain tissues and gene prod-
ucts are more sensitive than others to gene dosage effects
(Greber-Platzer et al. 1999; Tassone et al. 1999; Hattori
et al. 2000). The presence of tissue-specific epigenetic
and biochemical adaptive responses to overexpressed
genes greatly complicates the interpretation and impact
of gene overdosage in trisomic individuals. DNA se-
quence analysis is an essential first step toward identi-
fication of the trisomic genes (Yu et al. 1997; Hattori
et al. 2000), and the subsequent measurement of mRNA
transcript level provides an indication of the extent of
gene overexpression (Brodsky et al. 1997; Tassone et
al. 1999). However, the elucidation of tissue-specific bi-
ochemical and metabolic imbalance is likely to be more
useful in the clinical management of children with DS
(Lejeune 1990; Peeters et al. 1993). Although the per-
ception of DS as a metabolic disease is not yet prevalent,
the overexpression of genes coding for specific enzymes
translates directly into biochemical aberrations that af-
fect multiple interacting metabolic pathways and that
culminate in cellular dysfunction and contribute to the
unique pathogenesis of DS.
In the present study, we focused on a single gene on
chromosome 21 coding for the enzyme cystathionine b-
synthase (CBS) and on its indirect impact on one-carbon
metabolism, in children with DS. We hypothesized that
the plasma profile of the metabolites in the methionine/
homocysteine pathway in children with DS would be
consistent with a functional folate deficiency secondary
to overexpression of the CBS gene. The specific metab-
olites and metabolic pathways affected by CBS are sum-
marized in figure 1. A 157% increase in CBS enzyme
activity has been previously documented in individuals
with DS and has been associated with reduced levels of
homocysteine (Chadefaux et al. 1985, 1988). The one-
way CBS reaction condenses homocysteine with serine,
to effectively remove homocysteine from themethionine
cycle and to commit it to the transsulfuration pathway
for cysteine and glutathione synthesis (see fig. 1). An
increase in the transsulfuration pathway via CBS ov-
erexpression indirectly deprives themethionine synthase
reaction of one of its precursors, homocysteine, while,
at the same time, it promotes the accumulation of its
other precursor, 5-methyltetrahydrofolate (5-MTHF)
(Ueland et al. 1990). The decrease in the methionine
synthase activity thus creates the well-established
“methyl trap,” as a consequence of the one-way kinetics
of 5-MTHF synthesis (fig. 1). More important, a de-
crease in methionine synthase activity reduces the con-
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version of 5-MTHF to tetrahydrofolate (THF), the met-
abolically active form of folate, required for de novo
synthesis of nucleotides for RNA and DNA synthesis.
Because of the methyl trap, an intracellular functional
folate deficiency can exist in the presence of normal, or
even elevated, serum folate and B12 levels.
To define the specific imbalances induced by CBS ov-
erexpression, plasma levels of relevant metabolites and
lymphocyte DNA methylation status were measured in
children with DS and were compared to those from
normal siblings. The potential to correct the observed
metabolic imbalance via the in vitro addition of selected
nutrients to cultured human trisomy 21 lymphoblastoid
cells was also examined.
Subjects, Material, and Methods
Subjects and Blood Collection
Participants were 42 children with karyotypically con-
firmed full trisomy 21, as cases, and 36 normal siblings,
as controls. The mean  SD age of the children was
years. Exclusion criteria included antifolate7.4 4.2
medications, leukemia, and recent surgery. Written, in-
formed consent, approved by the Research Involving
Human Subjects Committee of the Food and Drug Ad-
ministration and by the University of Arkansas forMed-
ical Sciences Human Research Advisory Committee, was
obtained from the parents of all participants. A ques-
tionnaire was completed by each mother to indicate
whether, at the time of blood draw, the child was taking
either an over-the-counter vitamin pill or a commercially
available nutritional formula. Of the 42 children with
DS, 27 were taking a nutritional supplement, and 15
were not on any form of nutritional supplement; thus,
the study population was nutritionally heterogeneous.
Fasting blood samples were collected into EDTA Vacu-
tainer tubes, immediately chilled on ice, and centrifuged
at 400 g for 15 min at 4C. Aliquots of the plasma layer
were transferred into cryostat tubes and were stored at
80C until analysis. Aliquots were thawed for deter-
mination of plasma methionine, S-adenosylmethionine
(SAM), S-adenosylhomocysteine (SAH), adenosine, ho-
mocysteine, cystathionine, cysteine, and glutathione, by
high-performance liquid chromatography (HPLC).
Sample Preparation for Measurement of Plasma
Methionine, SAM, SAH, Adenosine, Homocysteine,
Cysteine, Cystathionine, and Glutathione
For determination of total homocysteine (tHcy), me-
thionine, cystathionine, cysteine, and total glutathione,
50 ml of freshly prepared 1.43-M sodium borohydride
solution containing 1.5 mM EDTA, 66 mM NaOH, and
10 ml of n-amyl alcohol were added to 200 ml of plasma
to reduce all sulfhydryl bonds. To precipitate proteins,
250 ml of ice-cold 10% metaphosphoric acid was added,
and the sample was incubated on ice for 10 min. After
centrifugation at 18,000 g for 15 min at 4C, the su-
pernatant was filtered through a 0.2-mm filter (PGC Sci-
entific), and a 20-ml aliquot was injected into the HPLC
system. For determination of SAM and SAH, 40 ml of
40% trichloroacetic acid were added to 200 ml of plasma
to precipitate protein, the solution was mixed well and
incubated on ice for 30 min. After centrifugation for 15
min at 18,000 g at 4C, supernatants containing SAM,
SAH, and adenosine were passed through a 0.2-mmfilter,
and a 20-ml aliquot was injected into the HPLC system.
HPLC with Coulometric Electrochemical Detection
The methodological details for metabolite elution and
electrochemical detection have been described elsewhere
(Melnyk et al. 1999, 2000). The analyses were accom-
plished byHPLCwith a Shimadzu solvent-delivery system
(model 580; ESA) and a reverse-phase C18 column (5 mm,
mm; MCM) obtained from ESA. A 20-ml al-4.6# 150
iquot of plasma extract was directly injected onto the
column by a Beckman autosampler (model 507E). All
plasma metabolites were quantified by a Coulochem II
electrochemical detector (model 5200A; ESA) equipped
with a dual analytical cell (model 5010) and a guard cell
(model 5020). The concentrations of plasma metabolites
were calculated from peak areas and standard calibration
curves, by HPLC software.
Cytosine-Extension Assay to Assess Lymphocyte Global
DNA Methylation
Lymphocytes were isolated in a random subset of chil-
dren by Histopaque-1077 reagent (Sigma Diagnostics).
Genomic DNAwas extracted via standard phenol/chlo-
roform procedures (Ausebel et al. 1989, pp. 2.3.1.–
2.3.3). In brief, the cytosine-extension assay for global
DNA methylation measures the extent of radiolabel in-
corporation into DNA, after treatment with a methyl-
ation-sensitive endonuclease that leaves a single guanine
overhang at unmethylated CpG sites. Details of the cy-
tosine-extension assay for DNA methylation have been
described elsewhere (Pogribny et al. 1999). The [3H]-
dCTP hybridizes to the exposed guanine, in proportion
to the number of unmethylated (cleaved) sites in DNA.
Thus, an increase in radiolabel incorporation reflects a
relative increase in global DNA hypomethylation, and,
conversely, lower radiolabel incorporation reflects rela-
tive hypermethylation. Results are expressed as the rel-
ative [3H]-dCTP/0.5 mg of DNA.
Trisomy 21 Cell Line and Cell-Culture Reagents
A human trisomy 21 lymphoblastoid cell line was ob-
tained from Coriell Cell Repositories. Cells were main-
tained in Roswell Park Memorial Institute (RPMI) 1640
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Table 1
Plasma Levels of tHcy, Methionine, Cystathionine, Cysteine, and Glutathione, in Children with DS and in
Controls
SUBJECTS
MEAN  SD PLASMA LEVEL
(mmol/liter)
tHcy Methionine Cystathionine Cysteine Glutathione
Children with DS ( )np 42 5.1  1.1* 16.1  3.3* .7  .2* 233.5  21.7* 6.9  1.4*
Controls ( )np 36 6.7  1.6 30.6  6.5 .2  .05 203.7  20.0 8.0  1.2
* .P ! .001
growth medium (Gibco BRL), 10% fetal bovine serum
(Hyclone Laboratories), and 1% penicillin-streptomycin
(Gibco BRL). Purified methionine, folinic acid, SAM,
thymidine, and dimethylglycine (DMG) were obtained
from Sigma-Aldrich. Methyl-B12 was a generous gift
from Enzymatic Therapy. Because differences in cell
growth rates could potentially affect metabolite concen-
trations, pilot studies were conducted to confirm that all
cells would be in log-phase growth at the time of harvest.
Supplementation, with Specific Nutrients, of Trisomy
21 Lymphoblastoid Cells
Human trisomy 21 lymphoblasts were seeded, at
cells/ml, in folic acid–free RPMI 1640 me-60.2# 10
dium adjusted to a final concentration of 50 ng of folic
acid/ml and 10 mmol of methionine/liter. The concen-
trations of the nutrients added to the culture medium in
six replicate wells were as follows: folinic acid (100 mM),
methyl-B12 (2 mg/liter), thymidine (20 mM), methionine
(100 mM), and DMG (50 mM). In order to maintain a
constant level of nutrients until harvest at day 7, the top
half of the medium in each well was carefully aspirated
and replaced, without disturbing the cells at the bottom.
Control wells contained trisomy 21 lymphoblastoid cells
cultured in RPMI growth medium without nutrient
addition.
Statistics
Data are presented as the mean SD. Statistical dif-
ferences between means were calculated with Student’s
t-test and SigmaStat software (Jandel Scientific).
Results
Plasma Concentrations of Methionine, tHcy,
Cystathionine, Cysteine, and Glutathione, in Children
with DS and in Controls
The children with DS had significantly altered plasma
levels of each of the metabolites, in the methionine/ho-
mocysteine pathway and also in theCBS-mediated trans-
sulfuration pathway (table 1). Plasma tHcy was 76% of
that of the control children, and plasma methionine level
was only 53% of that for the controls ( ). TheP ! .001
observed 3.8-fold increase in plasma cystathionine rep-
resents the first demonstration that the product of the
CBS reaction is significantly elevated, despite the pres-
ence of adaptive mechanisms to down-regulate gene ex-
pression and enzyme activity. The significant increase in
cysteine in the children with DS confirms previous ob-
servations (Lejeune et al. 1992) and may reflect a bot-
tleneck at the rate-limiting step for glutathione synthesis.
Finally, the significant decrease in plasma glutathione in
the children with DS is consistent with previous reports
of intracellular oxidative-stress increase due to over-
expression of the Cu-Zn superoxide dismutase gene
(SOD), which is also located on chromosome 21 (Ian-
nello et al. 1999).
Plasma Concentrations of SAM, SAH, and
Adenosine—and Lymphocyte DNA Methylation
Status—in Children with DS and in Controls
Methionine is the precursor for the ATP-dependent
synthesis of SAM, the universal methyl donor for essen-
tial cellular methylation reactions. In association with
the reduced plasma methionine levels, the level of SAM
was also significantly reduced in the children with DS,
as presented in table 2. In addition, a significant decrease
in plasma SAH, the product of SAM-dependent meth-
ylation reactions, was observed in the children with DS.
The decrease in both SAM and SAH is consistent with
a generalized depression in cellular methylation capacity
in these children. Interestingly, plasma adenosine levels
were significantly elevated in the children with DS com-
pared to those in the controls. The increase in adenosine
is consistent with an adaptive up-regulation of adenosine
deaminase and with the increase in uric acid levels, both
of which have been reproducibly documented in children
with DS (Puukka et al. 1986). Finally, the level of lym-
phocyte DNA hypomethylation was measured, to assess
an endpoint that might be negatively affected by reduced
levels of SAM and by reduced methylation capacity. Sur-
prisingly, the lymphocyte DNA from the children with
DS had decreased radiolabel incorporation, compared
to that in the controls, indicating that the DNA was
relatively hypermethylated, despite depressed levels of
SAM and SAH.
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Table 2
Plasma Levels of SAM, SAH, and Adenosine—and Lymphocyte DNA Methylation Status—in Children with DS and in
Controls
SUBJECTS
MEAN  SD PLASMA LEVEL
(nmol/liter)
GLOBAL DNA
METHYLATION
(dpm/0.5 mg DNA)aSAM SAH Adenosine
Children with DS 80.9  13.4 (n p 42)** 15.7  3.8 (n p 42)** 1.0  .5 (n p 42)* 4,540  505 (n p 17)*
Controls 98.3  15.7 (n p 36) 20.0  4.2 (n p 36) .75  .31 (n p 36) 4,954  542 (n p 12)
a Decrease in dpm indicates relative hypermethylation.
* .P ! .04
** .P ! .001
In Vitro Supplementation, with Selected Nutrients, of
Trisomy 21 Lymphoblastoid Cells
The choice of nutrients for in vitro supplementation
was based on the potential of each nutrient to augment
the synthesis of specific metabolites, shown, in table 1,
to be depressed in the children with DS. The specific
metabolites depleted in the children with DS appear to
be the indirect result of the inappropriate increase in
CBS activity and of the consequent permanent removal
of homocysteine from the folate-dependent homocyste-
ine/methionine cycle. As presented in table 3, the in vitro
addition of 100 mM methionine doubled intracellular
methionine and significantly increased levels of SAM,
SAH, and adenosine. The addition of 100 mM folinic
acid significantly increased tHcy, methionine, cysteine,
and SAM. Methyl-B12, at a final concentration of 2 mg/
liter, increased tHcy, methionine, SAM, SAH, and cys-
teine. Thymidine and DMGwere added, separately, both
to support folate-dependent thymidylate and DNA syn-
thesis and to augment one-carbon units available for
methionine synthesis. Both methionine and SAM were
increased by the addition of 20 mM thymidine. DMG
converts THF to 5,10-methylenetetrahydrofolate in mi-
tochondria and should also indirectly spare one-carbon
units for the methionine cycle. The addition of 50 mM
of DMG significantly increased tHcy, methionine, SAM,
SAH, and cysteine in the trisomy 21 lymphoblastoid
cells. Taken together, these results suggest that selective
nutritional intervention in vitro can shift one-carbonme-
tabolism in trisomy 21 cells.
Discussion
The plasma profile of the metabolites involved in the
methionine/homocysteine pathway in children with DS
is consistent with a functional folate deficiency second-
ary to CBS overexpression and the folate trap. Several
clinical observations suggest that children with DS may
be functionally folate deficient despite normal plasma
levels of folate and B12. For example, profound meth-
otrexate sensitivity (Ueland et al. 1990; Peeters et al.
1995), increased mean corpuscular volume (Gericke et
al. 1977), and gastrointestinal malabsorption (Jannson
and Johansson 1995) are often present in children with
DS and have also been associated with clinical folate
deficiency. Deoxynucleotide-pool imbalance, increased
folate-sensitive fragile sites, and DNA strand breaks are
induced by folate deprivation and have been docu-
mented in cells from individuals with DS (Gericke et al.
1977; Taub et al. 1996; Smith and Borsatto 1998).
Moreover, these lesions are associated with increased
risk of neoplastic transformation and may relate to in-
creased risk of leukemia in children with DS (Taub et
al. 1996).
The significant decrease in plasma methionine levels
observed in the children with DS most likely reflects a
decrease in methionine synthase activity, secondary to
CBS-mediated removal of its precursor, homocysteine.
The 50% decrease in methionine is of particular clinical
concern because of the central importance of methio-
nine in maintaining protein synthesis for growth, acute-
phase protein/antibody synthesis, and peptide-hormone
synthesis. In addition, methionine is the sole precursor
for the synthesis of SAM, the primary methyl donor for
essential cellular methylation reactions (fig. 1). An adap-
tive metabolic response to reduced intracellular levels
of methionine and SAM is the breakdown of phospha-
tidylcholine to choline and betaine (trimethylglycine
[TMG]). The enzyme betaine-homocysteine methyl-
transferase (BHMT) transfers a methyl group from be-
taine to homocysteine and provides an important al-
ternative route for endogenous methionine synthesis
when folate is limited (or trapped). A progressive de-
pletion of plasma choline levels via controlled folate
deprivation in humans has recently been documented
(Jacob et al. 1999). Individuals with DS have increased
sensitivity to anticholinergic drugs (Sacks and Smith
1989) and altered membrane phospholipid content and
fluidity (Scott et al. 1994), both of which can be ex-
plained by increased catabolism and depletion of cho-
line for methionine resynthesis.
The significant decreases, in both SAM and SAH, in
the plasma of the children with DS suggest a general
depression in cellular methylation capacity in these chil-
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Table 3
Intracellular tHcy, Methionine, Cysteine, Glutathione, SAM, and SAH Levels, in Trisomy 21 Lymphoblastoid Cells (AG 09802 Cell
Line) Grown Either in Medium Supplemented with Selected Nutrients or in Control RPMI Medium
SUPPLEMENT
(CONCENTRATION)
MEAN  SD INTRACELLULAR LEVELa
(nmol/mg protein)
tHcy Methionine Cysteine Glutathione SAM SAH Adenosine
Methionine (100 mM) .26  .06 14.7  2.4* 31.8  3.2** 49.1  4.1** .64  .1** .16  .04* 1.73  .7
Folinic acid (100 mM) .34  .06* 11.3  1.7* 48.5  3.1** 47.8  10.5 .52  .1* .12  .04 1.07  .2
Methyl-B12(2 mg/liter) .37  .06* 11.4  1.9* 51.4  3.5** 49.0  6.9* .52  .1* .19  .05* 1.56  .5
Thymidine (20 mM) .23  .04 12.4  2.4* 39.9  3.1 37.0  5.1 .48  .1* .15  .06 1.04  .2
DMG (50 mM) .35  .07* 14.3  3.3** 39.5  7.7* 39.5  7.7 .62  .1** .15  .02* 2.00  .8*
None .25  .04 7.4  .04 35.8  5.0 40.3  5.4 .31  .01 .09  .03 1.08  .2
a For six wells/nutrient.
* .P ! .04
** .P  .001
dren. The observed increase in global DNA methylation
in lymphocytes of the children with DS was unexpected
in the context of reduced SAM and SAH levels. It is
possible that the reduced SAM reflects increased meth-
ylation demands, as well as reduced synthesis. A recent
analysis of the proximal 20 kb of chromosome 21 re-
vealed a high proportion (46%) of interspersed repetitive
sequences that are densely methylated (190%) (Yu et al.
1997). It is possible that the observed increase in ge-
nomewide lymphocyte DNA methylation reflects the ad-
dition of the third highly methylated chromosome 21.
An alternative explanation is that the higher DNAmeth-
ylation density reflects an adaptive mechanism to down-
regulate overexpressed genes on chromosome 21. Gene
overdosage in normal females with two copies of the X
chromosome is regulated by promoter-region methyla-
tion on the inactive X chromosome, resulting in tran-
scriptional silencing of all genes on the inactive X chro-
mosome. Consistent with an increase in de novo
methylation as a mechanism to silence overexpressed
genes, the promoter region of the h2-calponin gene on
chromosome 21 was recently shown to be hypermeth-
ylated and down-regulated in individuals with DS (Ku-
romitsu et al. 1997). Of additional relevance to methyla-
tion dysregulation in DS is the recent discovery of a new
de novo DNA methyltransferase gene, known as
“DNMT3L,” located on chromosome 21, although its
functional significance is not yet known (Aapola et al.
2000). Further evidence for protein-methylation dys-
function is provided by the observation that individuals
with DS synthesize reduced levels of methylnicotinamide
after a nicotinamide load, indicating a reduced protein-
methylation capacity (Gershoff and Hegsted 1958). Fi-
nally, evidence of delayed myelination of DS neurons is
consistent with reduced methylation of myelin basic pro-
tein (Wisniewski and Schmidt-Sidor 1989).
The increase in plasma adenosine levels in the chil-
dren with DS is consistent with previous observations.
The increase in plasma adenosine and in adenosine de-
aminase activity is strongly correlated with hyperuri-
cemia in individuals with DS (Puukka et al. 1986). It
has been suggested that hyperuricemia in individuals
with DS is due to excessive purine synthesis resulting
from overexpression of the gene for de novo purine
synthesis, GARS-AIRS-GART, which is located on
chromosome 21 (Peeters et al. 1993). Although in-
creased mRNA transcripts for this gene have been doc-
umented both prenatally and during the early postnatal
period (Brodsky et al. 1997), evidence for an increase
in enzyme activity is lacking. The observations in the
present study suggest an alternative explanation for in-
creased uric acid production in DS. The overexpression
of CBS would result in an enhanced flux of methionine
metabolites down the transsulfuration pathway, result-
ing in excess production of adenosine from SAH hy-
drolysis (fig. 1). In addition, the methyl trap in individ-
uals with DS would reduce the availability of folate for
de novo synthesis of the purine ring (Ueland et al. 1990).
Therefore, we suggest that the hyperuricemia in DS re-
flects increased adenosine production secondary to CBS
overexpression and is not the result of increased de novo
purine synthesis.
The reduced plasma glutathione observed in the chil-
dren with DS most likely reflects an adaptive antioxi-
dant response to chronic oxidative stress, resulting from
SOD overexpression (fig. 1). The 3.8-fold increase in
intracellular cystathionine is the first documentation
that the product of the CBS reaction is highly elevated
in the children with DS. Elevated cystathionine is not
likely to have pathological consequences, however, since
children with an inactivating mutation in cystathionine
g-lyase exhibit cystathioninuria but no associated pa-
thology (Mudd et al. 1995). The presence of both CBS
and SOD on chromosome 21 may be fortuitous, since
the end product of CBS transsulfuration, glutathione,
serves as a major antioxidant, by detoxifying H2O2, the
product of SOD. The increase in plasma cysteine is sig-
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nificant but not excessive and provides substrate for
glutathione synthesis.
The modulation of the metabolites in the homocyste-
ine/methionine cycle, via in vitro addition of selected
nutrients, is not surprising. Nutritional intervention
with high doses of folic acid and B12 in patients with
homocysteinemia has proved to be a successful clinical
intervention to modulate these pathways and to restore
normal homocysteine levels and one-carbon homeosta-
sis (Brattstro¨m et al. 1998). Because individuals with
DS have low homocysteine levels and a high probability
of a folate trap (Ueland et al. 1990), intervention with
folinic acid (5-formyltetrahydrofolate) has several ad-
vantages over intervention with folic acid. This form of
folate is more efficiently absorbed as the reduced me-
tabolite, is rapidly polyglutamated, and is more readily
available for folate-dependent reactions (Priest et al.
1991). Although DMG successfully increased methio-
nine levels in the cultured trisomy 21 lymphoblastoid
cells, intervention with betaine, or TMG, would have
the additional advantage of providing the folate-inde-
pendent mechanism for methionine resynthesis fromho-
mocysteine. In the present study, DMG, rather than
TMG, was used because lymphoid cells do not express
the BHMT gene. The BHMT gene is primarily expressed
in liver and kidney, and betaine has been used success-
fully to treat children with congenital defects in homo-
cysteine metabolism (Wilcken et al. 1983). The increase
in SAH levels that occurs with in vitro nutritional sup-
plementation suggests that cellular methylation reac-
tions were stimulated in these cells. On the basis of both
(a) these encouraging in vitro findings and (b) successful
clinical trials with these nutrients in patients with hom-
ocysteinemia, clinical intervention with folinic acid and
betaine is worthy of investigation.
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